[go: up one dir, main page]

WO2018112365A3 - Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii - Google Patents

Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii Download PDF

Info

Publication number
WO2018112365A3
WO2018112365A3 PCT/US2017/066713 US2017066713W WO2018112365A3 WO 2018112365 A3 WO2018112365 A3 WO 2018112365A3 US 2017066713 W US2017066713 W US 2017066713W WO 2018112365 A3 WO2018112365 A3 WO 2018112365A3
Authority
WO
WIPO (PCT)
Prior art keywords
melanoma
methods
colorectal cancer
parabacteroides goldsteinii
treating colorectal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/066713
Other languages
French (fr)
Other versions
WO2018112365A2 (en
Inventor
Brian Goodman
Peter SANDY
Jacqueline PAPKOFF
Holly PONICHTERA
Maria SIZOBA
Mark BODMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evelo Biosciences Inc
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of WO2018112365A2 publication Critical patent/WO2018112365A2/en
Publication of WO2018112365A3 publication Critical patent/WO2018112365A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided herein are methods and compositions related to Parabacteroides goldsteinii useful as therapeutic agents for the treatment of colorectal cancer and/or melanoma.
PCT/US2017/066713 2016-12-16 2017-12-15 Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii Ceased WO2018112365A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662435603P 2016-12-16 2016-12-16
US62/435,603 2016-12-16

Publications (2)

Publication Number Publication Date
WO2018112365A2 WO2018112365A2 (en) 2018-06-21
WO2018112365A3 true WO2018112365A3 (en) 2018-09-20

Family

ID=60991551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/066713 Ceased WO2018112365A2 (en) 2016-12-16 2017-12-15 Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii

Country Status (1)

Country Link
WO (1) WO2018112365A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
LT3193901T (en) 2014-12-23 2018-06-11 4D Pharma Research Limited Pirin polypeptide and immune modulation
EP3065748B1 (en) 2014-12-23 2017-11-22 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
ES2748812T3 (en) 2015-06-15 2020-03-18 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
RS63089B1 (en) 2015-06-15 2022-04-29 4D Pharma Res Ltd Compositions comprising bacterial strains
PT3240554T (en) 2015-06-15 2019-11-04 4D Pharma Res Ltd Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
SI3209310T1 (en) 2015-11-20 2018-06-29 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TWI802545B (en) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018187272A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
TWI787272B (en) 2017-05-22 2022-12-21 英商4D製藥研究有限公司 Compositions comprising bacterial strains
JP6978514B2 (en) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited Composition containing bacterial strain
ES2841902T3 (en) 2017-06-14 2021-07-12 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2018229236A2 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
KR20210008391A (en) 2018-05-11 2021-01-21 4디 파마 리서치 리미티드 Composition containing bacterial strain
WO2020079024A1 (en) 2018-10-15 2020-04-23 Pharmabiome Ag Consortia of living bacteria useful for treatment of colorectal cancer
TWI733222B (en) * 2018-10-31 2021-07-11 星聚樊生物科技有限公司 Use of parabacteroides goldsteinii for treating lung cancer
WO2020093040A1 (en) * 2018-11-02 2020-05-07 The Regents Of The University Of California Methods to diagnose and treat cancer using non-human nucleic acids
BR112021010917A2 (en) 2018-12-12 2021-08-31 4D Pharma Research Limited COMPOSITIONS COMPRISING PARABACTEROID BACTERIAL STRAINS FOR TREATMENT OF CANCER
TWI716249B (en) * 2019-01-25 2021-01-11 星聚樊生物科技有限公司 Use of lipopolysaccharide of parabacteroides goldsteinii to inhibit inflammation
CA3132338A1 (en) 2019-04-05 2020-10-08 David Suhy Improved methods and compositions for synthetic biomarkers
CN110279862B (en) * 2019-07-09 2022-04-08 上海市第六人民医院 Anticancer composition and application thereof in preparing medicine for treating osteosarcoma
US11883447B2 (en) * 2019-09-18 2024-01-30 Research Development Foundation Methods and probiotic compositions for the treatment of metabolic diseases and disorders
TW202216169A (en) * 2020-10-27 2022-05-01 星聚樊生物科技有限公司 Use of hypo-acylated lps for anti-oxidation and prevention/treatment of diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130540A1 (en) * 2013-02-22 2014-08-28 The Regents Of The University Of California Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
US20160243175A1 (en) * 2013-10-03 2016-08-25 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
WO2016149449A1 (en) * 2015-03-18 2016-09-22 Tufts University Compositions and methods for preventing colorectal cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1725660T3 (en) 2004-03-05 2011-08-29 Benitec Inc Expression cassettes with multiple promoters for simultaneous delivery of RNAi agents
AR069328A1 (en) 2007-11-15 2010-01-13 Alcon Mfg Ltd RELEASE OF SHORT OR SIRNA INTERFERENT RNA, INTERMEDIATED BY LOW DENSITY LIPOPROTEIN RECEPTOR
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
DK2539451T3 (en) 2010-02-24 2016-04-04 Arrowhead Res Corp Compositions for targeted delivery of siRNA
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
ES2605990T3 (en) 2010-12-29 2017-03-17 F. Hoffmann-La Roche Ag Small molecule conjugates for intracellular administration of nucleic acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130540A1 (en) * 2013-02-22 2014-08-28 The Regents Of The University Of California Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
US20160243175A1 (en) * 2013-10-03 2016-08-25 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
WO2016149449A1 (en) * 2015-03-18 2016-09-22 Tufts University Compositions and methods for preventing colorectal cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. KVERKA ET AL: "Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 163, no. 2, 19 February 2011 (2011-02-19), GB, pages 250 - 259, XP055295102, ISSN: 0009-9104, DOI: 10.1111/j.1365-2249.2010.04286.x *

Also Published As

Publication number Publication date
WO2018112365A2 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2015011898A (en) Pyrazolo compounds and uses thereof.
JOP20200022A1 (en) Spirocycle compounds and methods of making and using same
UA119458C2 (en) Pladienolide pyridine compounds and methods of use
ZA201900960B (en) Methods and compositions for the treatment of cancer
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
CR20200089A (en) Spirocycle compounds and methods of making and using same
MX2016014436A (en) Heterocyclyl-butanamide derivatives.
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
MX2017006026A (en) Apilimod for use in the treatment of colorectal cancer.
WO2019023315A3 (en) RAC INHIBITORS
MX392475B (en) A solid state form of pladienolide pyridine compounds and methods of use
WO2016094374A8 (en) Compositions and methods for treatment of friedreich's ataxia
PH12016501838A1 (en) Compounds and their methods of use
ZA201808232B (en) Compositions and methods for the treatment of cancer
MX383947B (en) Collagen 7 compositions and methods of using the same
MY182818A (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
SG11202000724XA (en) Methods and compositions for the treatment of cancer
MX2019004179A (en) Apilimod compositions and methods for using same in the treatment of alzheimer's disease.
WO2019028012A3 (en) Methods of using pembrolizumab and trebananib
MY182809A (en) Compositions for the treatment of kidney and/or liver disease
HK1242965A1 (en) Apilimod for use in the treatment of colorectal cancer
HK1237265A1 (en) Combination therapy compositions and methods for treating cancers
HK40029034A (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17829798

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17829798

Country of ref document: EP

Kind code of ref document: A2